Thermo Fisher Scientific recently unveiled its ambitious plans to bolster India’s biopharma landscape through significant investments aimed at enhancing manufacturing capabilities. The announcement was made during the Biopharma Conclave 2025 in Hyderabad, where key stakeholders from government, industry, and academia converged. The company is set to establish two cutting-edge facilities in Genome Valley by the end of 2025. The Bioprocess Design Center (BDC), developed in collaboration with the Telangana Government, will focus on accelerating the development of transformative therapies by leveraging expertise in bioprocessing and scale-up. Additionally, the Customer Experience Center (CEC) is designed to showcase advanced instrumentation and workflows spanning molecular biology, proteomics, diagnostics, and cell and gene therapy, while also supporting industry upskilling initiatives.
With a firm commitment to India, Thermo Fisher Scientific aims to provide access to technology and skill-building opportunities through its state-of-the-art facilities in Hyderabad. The biopharmaceutical market in India stood at $8.1 billion in 2024 and is projected to nearly double to $15.9 billion by 2030. Factors driving this growth include market maturation, favorable regulatory environments globally, and significant unmet clinical needs within the country. Tony Acciarito, President of Asia Pacific & Middle East, Africa at Thermo Fisher Scientific, emphasized the company’s role in fostering innovation, increasing productivity, and upholding quality standards for its customers. The strategic expansion in Genome Valley underscores the company’s dedication to supporting India’s burgeoning biopharma sector.
Key to Thermo Fisher’s growth strategy are the planned facilities in Hyderabad, scheduled to be operational by the end of 2025. The BDC will play a pivotal role in expediting the development of life-altering therapies, while the CEC will feature subject matter experts to facilitate method development, technology adoption, and industry upskilling. Srinath Venkatesh, Managing Director of India & South Asia at Thermo Fisher Scientific, highlighted the challenges faced by the Indian biopharma industry, such as limited access to cutting-edge technologies and expertise. The BDC and CEC are poised to address these challenges head-on, empowering both startups and established companies to accelerate their time-to-market strategies and ensure compliance with stringent international quality standards.
The Biopharma Conclave, organized by CPHI, Informa Markets, delved into critical topics including the advancement of biologics, cell and gene therapies, workforce development, and the promotion of women in STEM fields. A leadership panel focused on navigating uncertainties in the biologics and biosimilars landscape, discussing the current pipeline and outlining projections for the next five years. Thermo Fisher Scientific’s proactive investments and collaborative initiatives in India are set to revolutionize the biopharma sector, driving innovation, fostering skill development, and paving the way for sustainable growth.
Key Takeaways:
– Thermo Fisher Scientific’s strategic investments in India aim to enhance biopharma manufacturing capabilities and support industry upskilling.
– The planned facilities in Genome Valley, Hyderabad, including the Bioprocess Design Center and Customer Experience Center, will play a crucial role in expediting therapy development and technology adoption.
– The company’s commitment to India’s biopharma sector underscores its dedication to fostering innovation, increasing productivity, and maintaining high-quality standards.
– Collaborative initiatives and investments by Thermo Fisher Scientific are poised to revolutionize the Indian biopharma landscape, driving growth and ensuring compliance with international standards.
Tags: gene therapy, regulatory, biosimilars, bioprocess, biopharma, proteomics
Read more on pharmabiz.com